Going forward..., page-1408

Recap:


2016:

“D&R Pharmaceuticals has already committed significant funds to contract research focussed on stem cell applications in regenerative medicine – research led by Professor Xin-Fu Zhou at UniSA’s School of Health Sciences.”

“Prof Lloyd says the benefits to the partnership extend beyond the University.

“Being able to attract successful partnerships to SA is very important because once the links have been made, there is potential for an expansion of relationships and in the case of D&R Pharmaceuticals, I know they will be keen to see how they can foster connections between SA research and pharmaceutical companies in China,” he says.“
https://www.unisa.edu.au/Media-Centre/Releases/2016-Media-releases/China-UniSA-partnership-to-spearhead-pharmaceutical-innovations/


10 May 2018:

“TekCyte is currently validating two CTM CRC technologies for the commercial market: the delivery of stem cells for the treatment of chronic wounds, and an antithrombotic coating for vascular stents to reduce thrombosis and restenosis. With positive preclinical data to date, it is imperative that TekCyte is able to consistently produce both products in large volumes, as well as meeting stringent regulatory requirements and demonstrating reliable performance. TekCyte’s infrastructure and expertise enables it to fulfil this critical translational role so it can bridge the gap between the laboratory and commercial development.”
https://sciencemeetsbusiness.com.au/tag/health-innovation/


6 March 2019:



CTM CRC holds 3 patent applications in relation to the wound patch and the project has led to the development of further projects. One such
project is with industry SME, Cynata, where the patch technology is being further developed to accommodate mesenchymal stem cells that are grown in serumfree conditions. Cynata’s Cymerus™ cells can be manufactured cost-effectively at a large scale, from a
single donor.

TekCyte and Cynata are now working with a partner in the UK towards a first-in-man trial to demonstrate the safety of this cell the
https://www.ctmcrc.com/wp-content/uploads/2019/03/2019CTMCRC-ExitReport_FINAL-lowres2.pdf



NOW:

10 December 2019:

"INVESTORS INJECT $45 MILLION INTO SA HEALTH AND BIOTECH INDUSTRY
Posted on Dec 10 2019 by David Ellis

The Adelaide China Biotech Investment Fund has today been launched – a new $45 million investment fund that will accelerate the development and commercialisation of health and bio-technologies from South Australia for the global market.

The $45 million fund is backed by a group of private investors based in Nanjing, China. The group is led by Mr An LuFan, Executive Director of D&R Pharmaceuticals, one of China’s leading drug development companies.

The fund will support the commercialisation of health and biotech research from South Australia, enabling researchers from the University of Adelaide, University of South Australia, the State’s hospitals and other institutions to develop proof of concept, undertake clinical trials, and ultimately bring new drugs and additional technologies into healthcare."
https://www.adelaide.edu.au/newsroom/news/list/2019/12/10/investors-inject-45-million-into-sa-health-and-biotech-industry


What are the odds that some of these funds will be used to accelerate woundcare, which is addressing a market size of US$3 billion?

CYP-003? We know of CYP-001, CYP-002 and CYP-004... (based on the timeline it would fit)